Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;111(10S1):10S5-10S18.
doi: 10.1016/S0007-4551(24)00404-1.

Nouveautés en pathologie thyroïdienne : classification OMS 2022, système Bethesda 2023, biologie moléculaire et testing moléculaire

[Article in French]
Mohamed Amine Bani  1 , Sophie Moog  2 , Voichita Suciu  3 , Livia Lamartina  2 , Abir Al Ghuzlan  4
Affiliations
Review

Nouveautés en pathologie thyroïdienne : classification OMS 2022, système Bethesda 2023, biologie moléculaire et testing moléculaire

[Article in French]
Mohamed Amine Bani et al. Bull Cancer. 2024 Oct.

Abstract

WHO CLASSIFICATION 2022, BETHESDA SYSTEM 2023, MOLECULAR BIOLOGY AND MOLECULAR TESTING: Thyroid pathology has experienced significant advances with the publication of the 5th edition of the World Health Organization classification of endocrine tumors in 2022 and the third edition of the Bethesda system for thyroid cytopathology in 2023. At the same time, the availability of next-generation sequencing data coupled with numerous translational research projects have considerably increased our knowledge of the genomics and mechanics of thyroid cancers, enabling us to refine prognosis and propose new targeted therapies. In this review, we will take up the main new features of the WHO 2022 and Bethesda 2023 classifications, as well as molecular biology findings, with an emphasis on the practical implications for clinicians.

Keywords: Bethesda system; Classification OMS; Cytopathologie thyroïdienne; Pathologie thyroïdienne; Système Bethesda; Thyroid cytopathology; Thyroid pathology; Thyroid tumors; Tumeurs thyroïdiennes; WHO classification.

PubMed Disclaimer

Conflict of interest statement

Liens d’intérêts S. Moog, M. Amine Bani, A. Al Ghuzlan et V. Suciu déclarent ne pas avoir de liens d’intérêts. L. Lamartina déclare des liens d’intérêts pour des financements pour participation à un congrès de la part des laboratoires AAA Novartis et Ipsen; pour participation à des tumor boards de la part des laboratoires Eisai et Ipsen; pour des honoraires perçus de la part des laboratoires Eisai, Lilly et Roche. Cet article fait partie du supplément Prise en charge des cancers thyroïdiens en 2024 : avancées diagnostiques et thérapeutiques réalisé avec le soutien institutionnel de Lilly.

MeSH terms

LinkOut - more resources